Tag: cardiovascular genetic testing market demand

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Cardiovascular Genetic Testing Market CAGR Analysis And Future Market Development

The cardiovascular genetic testing market has seen rapid expansion in recent years. Its size is expected to increase from $3.93 billion in 2025 to $4.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. The historical growth of this market can be attributed to several factors, including a rise in awareness regarding inherited cardiovascular disorders, the development of molecular diagnostic capabilities, a reduction in the costs associated with genetic sequencing, an increase in the adoption of genetic counseling services, and enhanced research into cardiovascular genomics.

The cardiovascular genetic testing market is projected for substantial expansion in the coming years, reaching a valuation of $6.62 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.0%. This anticipated growth during the forecast period stems from factors such as the escalating demand for precision medicine, the growing embrace of population-based genetic screening, the broadening scope of AI-driven variant interpretation, the deeper integration of genomics into clinical decision-making, and a heightened emphasis on preventive cardiovascular healthcare. Key trends expected over this period encompass a greater uptake of predictive genetic risk assessment, increased utilization of multigene panel testing, the advancing integration of bioinformatics and AI analytics, the widening application of pharmacogenomic testing, and a stronger commitment to personalized cardiovascular care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33054&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Jul_PR

Cardiovascular Genetic Testing Market Demand Drivers: What Is Fueling Industry Growth?

The rising occurrence of cardiovascular diseases is projected to drive the expansion of the cardiovascular genetic testing market moving forward. Cardiovascular diseases, or CVDs, refer to a collection of conditions impacting the heart and blood vessels, including ailments like heart attacks, strokes, and high blood pressure. The growing prevalence of these conditions is mainly due to an increase in sedentary lifestyles connected with urbanization, which contribute to obesity, hypertension, and metabolic disorders. The increasing incidence of cardiovascular diseases fuels the demand for cardiovascular genetic testing, as early detection of genetic risks allows for personalized prevention and treatment strategies to diminish the chance of severe heart complications. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, stated that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the escalating prevalence of cardiovascular disease is propelling the growth of the cardiovascular genetic testing market.

Cardiovascular Genetic Testing Market Segment Performance And Strategic Opportunities

The cardiovascular genetic testing market covered in this report is segmented –

1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types

2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases

3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing

4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications

5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing

Subsegments:

1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing

2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing

3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing

4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing

5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing

6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing

Cardiovascular Genetic Testing Market Innovation Trends: Which Developments Are Transforming The Industry?

Major companies within the cardiovascular genetic testing market are prioritizing the development of innovative solutions, such as tests initiated by clinicians. These solutions aim to guarantee the medical necessity of tests and customize them to a patient’s specific health profile, thereby decreasing unnecessary testing and associated costs. A clinician-ordered test is defined as a medical examination or diagnostic procedure requested by a healthcare professional to assess, monitor, or guide the management of an individual’s health condition. For example, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in partnership with Broad Clinical Labs, a US-based genomic data generation laboratory, and Mass General Brigham Laboratory for Molecular Medicine, a US-based molecular diagnostic laboratory, introduced a genetic test designed to evaluate inherited risk for eight cardiovascular conditions. This clinician-ordered test is provided on a self-pay basis and assesses genetic predisposition to the eight specified conditions: atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its creation leveraged genotype and clinical data from 236,393 participants in the NIH’s All of Us Research Program. Publicly available polygenic risk scores for each condition were integrated utilizing PRSmix, an elastic-net modeling approach that combines multiple component scores into a single, comprehensive risk score per disease. High-resolution genetic data is obtained through a clinical blended genome-exome assay at Broad Clinical Labs, with the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine then interpreting the results and generating accessible reports for patients.

Cardiovascular Genetic Testing Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.

Access The Complete Cardiovascular Genetic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/cardiovascular-genetic-testing-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Jul_PR

Cardiovascular Genetic Testing Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Cardiovascular Genetic Testing Market Between 2026 And 2030?

The market for cardiovascular genetic testing has experienced significant growth over the past few years. It is anticipated to expand from $3.93 billion in 2025 to $4.35 billion in 2026, at a compound annual growth rate (CAGR) of 10.8%. The growth observed in the past can be attributed to heightened awareness of inherited cardiovascular disorders, the broadening of molecular diagnostic capabilities, decreasing costs associated with genetic sequencing, an increase in the use of genetic counseling services, and more research in cardiovascular genomics.

The cardiovascular genetic testing market is set to experience substantial growth in the upcoming years, projected to reach $6.62 billion in 2030 with a compound annual growth rate (CAGR) of 11.0%. This expansion over the forecast period is driven by factors such as the increasing need for precision medicine approaches, a rise in the adoption of population-based genetic screening, the broader application of AI-driven variant interpretation, the growing integration of genomics into clinical decision making, and an increased focus on preventive cardiovascular healthcare. Significant trends expected during this period include the wider acceptance of predictive genetic risk assessment, a surge in the use of multigene panel testing, the deeper integration of bioinformatics and AI analytics, the expansion of pharmacogenomic testing applications, and an enhanced emphasis on personalized cardiovascular care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33054&type=smp

What Important Drivers Are Powering The Cardiovascular Genetic Testing Market Growth?

The increasing incidence of cardiovascular diseases is projected to drive the expansion of the cardiovascular genetic testing market moving forward. Cardiovascular diseases, or CVDs, encompass a range of conditions affecting the heart and blood vessels, such as heart attacks, strokes, and hypertension. The rise in cardiovascular disease prevalence is primarily attributed to increasingly sedentary lifestyles linked to urbanization, which foster obesity, high blood pressure, and metabolic disorders. This growing frequency of cardiovascular diseases stimulates demand for genetic testing, as early detection of genetic predispositions enables personalized prevention and treatment strategies to mitigate the risk of serious heart issues. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease reached 233.3 per 100,000 in 2024, indicating a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the rising prevalence of cardiovascular disease is a significant force propelling the growth of the cardiovascular genetic testing market.

Which Segment Groups Define The Cardiovascular Genetic Testing Market Landscape?

The cardiovascular genetic testing market covered in this report is segmented –

1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types

2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases

3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing

4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications

5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing

Subsegments:

1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing

2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing

3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing

4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing

5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing

6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing

What Trends Are Influencing The Cardiovascular Genetic Testing Market Outlook?

Leading companies in the cardiovascular genetic testing market are concentrating on developing innovative solutions, such as clinician-ordered tests, to ensure medical necessity and tailor them to a patient’s specific health condition, thereby reducing redundant testing and costs. A clinician-ordered test is defined as a medical examination or diagnostic procedure requested by a healthcare professional to assess, monitor, or guide the management of an individual’s health status. For instance, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in collaboration with Broad Clinical Labs, a US-based genomic data generation laboratory, and Mass General Brigham Laboratory for Molecular Medicine, a US-based molecular diagnostic laboratory, introduced a genetic test designed to evaluate inherited risk for eight cardiovascular conditions. This clinician-ordered test is offered on a self-pay basis and assesses genetic predisposition to eight conditions, which include atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its development incorporated genotype and clinical data from 236,393 participants in the NIH’s All of Us Research Program. Publicly available polygenic risk scores for each condition were integrated utilizing PRSmix, an elastic-net modeling approach that combines multiple component scores into a single, comprehensive risk score per disease. High-resolution genetic data is captured through a clinical blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine is responsible for interpreting the results and generating patient-friendly reports.

Which Firms Are Competing In The Cardiovascular Genetic Testing Market?

Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.

Access The Complete Cardiovascular Genetic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/cardiovascular-genetic-testing-market-report

What Is The Largest Regional Market In The Cardiovascular Genetic Testing Market?

North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Cardiovascular Genetic Testing Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Cardiovascular Genetic Testing Market Projected To Reach By 2030?

The cardiovascular genetic testing market size has recently experienced rapid expansion. This market is projected to grow from $3.93 billion in 2025 to $4.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. Historically, this growth can be attributed to several factors including increasing awareness of inherited cardiovascular disorders, the expansion of molecular diagnostic capabilities, the declining costs of genetic sequencing, the growing use of genetic counseling services, and increased research in cardiovascular genomics.

The cardiovascular genetic testing market size is projected to experience significant expansion in the coming years, with an expected increase to $6.62 billion by 2030, reflecting a compound annual growth rate (CAGR) of 11.0%. This growth during the forecast period is primarily driven by the escalating demand for precision medicine, the rising acceptance of population-based genetic screening, the expanding use of AI in variant interpretation, the increasing integration of genomics into clinical decision-making, and a heightened focus on preventive cardiovascular healthcare. Major developments anticipated in this period include the increased adoption of predictive genetic risk assessment, the rising utilization of multigene panel testing, the deeper integration of bioinformatics and AI analytics, the broadening applications of pharmacogenomic testing, and an enhanced emphasis on personalized cardiovascular care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33054&type=smp

Which Key Factors Are Driving The Cardiovascular Genetic Testing Market Growth?

The escalating incidence of cardiovascular diseases is projected to spur the expansion of the cardiovascular genetic testing market in the foreseeable future. Cardiovascular diseases (CVDs) represent a category of ailments affecting the heart and blood vessels, encompassing conditions such as heart attacks, strokes, and hypertension. The rise in cardiovascular disease prevalence is primarily due to increasingly sedentary lifestyles linked to urbanization, which contribute to conditions like obesity, hypertension, and various metabolic disorders. This growing occurrence of cardiovascular diseases boosts the demand for cardiovascular genetic testing, as early detection of genetic risks allows for personalized prevention and treatment strategies aimed at diminishing the likelihood of severe heart complications. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, an increase of 4.0% from 224.4 per 100,000 in 2023. Thus, the rising prevalence of cardiovascular disease is a significant catalyst for the growth of the cardiovascular genetic testing market.

Which Segment Classifications Are Used In The Cardiovascular Genetic Testing Market Segment Analysis?

The cardiovascular genetic testing market covered in this report is segmented –

1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types

2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases

3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing

4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications

5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing

Subsegments:

1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing

2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing

3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing

4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing

5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing

6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing

Which Trends Are Guiding The Direction Of The Cardiovascular Genetic Testing Market?

Leading companies within the cardiovascular genetic testing market are prioritizing the creation of novel solutions, such as clinician-ordered tests. These tests aim to confirm medical necessity and customize testing to a patient’s specific health status, thereby cutting down on redundant testing and expenses. A clinician-ordered test is a medical examination or diagnostic process initiated by a healthcare professional to assess, monitor, or guide a patient’s health management. For instance, in September 2025, Mass General Brigham, a US-based integrated academic healthcare system, in partnership with Broad Clinical Labs, a US-based genomic data generation laboratory, and Mass General Brigham Laboratory for Molecular Medicine, a US-based molecular diagnostic laboratory, introduced a genetic test. This test assesses the inherited risk for eight cardiovascular conditions, including atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Offered on a self-pay basis, its development leveraged genotype and clinical data from 236,393 individuals from the NIH’s All of Us Research Program. The integration of publicly available polygenic risk scores for each condition was achieved using PRSmix, an elastic-net modeling approach that combines multiple component scores into a single, comprehensive risk score per disease. High-resolution genetic data is gathered through a clinical blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine is responsible for interpreting the findings and generating patient-friendly reports.

Which Firms Are Contributing To The Cardiovascular Genetic Testing Market Ecosystem?

Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.

Get The Full Cardiovascular Genetic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/cardiovascular-genetic-testing-market-report

Which Region Has The Greatest Market Share In The Cardiovascular Genetic Testing Market?

North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cardiovascular Genetic Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=33054&type=smp

Browse Through More Reports Similar to the Global Cardiovascular Genetic Testing Market 2026, By The Business Research Company

Cardiovascular Clinical Trials Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-clinical-trials-global-market-report

Genetic Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Direct To Consumer Dtc Genetic Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/direct-to-consumer-dtc-genetic-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Cardiovascular Genetic Testing Market Over The Period 2026–2030?

The cardiovascular genetic testing market size has seen rapid expansion in recent years. It is anticipated to expand from $3.93 billion in 2025 to $4.35 billion in 2026, at a compound annual growth rate (CAGR) of 10.8%. This growth observed in previous periods is attributable to heightened awareness of inherited cardiovascular conditions, the enlargement of molecular diagnostic capabilities, the decreasing costs of genetic sequencing, an increase in the utilization of genetic counseling services, and expanded research within cardiovascular genomics.

The cardiovascular genetic testing market size is poised for substantial growth over the upcoming years, with projections indicating it will expand to reach **$6.62 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%**. This anticipated expansion during the forecast period is driven by factors such as a rising need for precision medicine approaches, increasing implementation of population-based genetic screening, the development of AI-driven variant interpretation, greater integration of genomics into clinical decision-making, and a heightened emphasis on preventive cardiovascular healthcare. Prominent trends expected in this period include the wider adoption of predictive genetic risk assessments, an increase in the utilization of multigene panel testing, enhanced incorporation of bioinformatics and AI analytics, the widening scope of pharmacogenomic testing applications, and an intensified focus on customized cardiovascular care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33054&type=smp

Which Economic Or Industry Drivers Are Impacting The Cardiovascular Genetic Testing Market?

The rising incidence of cardiovascular diseases is anticipated to drive the future expansion of the cardiovascular genetic testing market. Cardiovascular diseases (CVDs) refer to a range of conditions that impact the heart and blood vessels, including ailments such as heart attacks, strokes, and high blood pressure. The escalation in cardiovascular disease prevalence is largely attributed to increasingly sedentary lifestyles linked to urbanization, which contribute to conditions like obesity, hypertension, and various metabolic disorders. This growing frequency of cardiovascular diseases stimulates demand for cardiovascular genetic testing, as identifying genetic risks early allows for tailored prevention and treatment plans to diminish the chances of severe heart complications. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, an increase of 4.0% from 224.4 per 100,000 in 2023. Thus, the increasing occurrence of cardiovascular disease is a key factor propelling the growth of the cardiovascular genetic testing market.

How Is The Cardiovascular Genetic Testing Market Divided Into Its Major Segments?

The cardiovascular genetic testing market covered in this report is segmented –

1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types

2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases

3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing

4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications

5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing

Subsegments:

1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing

2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing

3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing

4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing

5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing

6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing

How Are Trends Transforming The Cardiovascular Genetic Testing Market Landscape?

Leading companies in the cardiovascular genetic testing market are concentrating on creating innovative solutions, such as clinician-ordered tests, to help ensure medical necessity and tailor testing to a patient’s specific health condition, thereby reducing unnecessary procedures and costs. A clinician-ordered test involves a medical examination or diagnostic procedure requested by a healthcare professional to assess, monitor, or guide the management of a patient’s health status. For instance, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in collaboration with Broad Clinical Labs, a US-based genomic data generation laboratory, and Mass General Brigham Laboratory for Molecular Medicine, a US-based molecular diagnostic laboratory, introduced a genetic test designed to evaluate inherited risk for eight cardiovascular conditions. This clinician-ordered test is offered on a self-pay basis and assesses genetic predisposition to eight conditions, including atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its development utilized genotype and clinical data from 236,393 participants in the NIH’s All of Us Research Program. Publicly available polygenic risk scores for each condition were integrated using PRSmix, an elastic-net modeling approach that combines multiple component scores into a single, comprehensive risk score per disease. High-resolution genetic data is captured through a clinical blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine interprets the results and generates patient-friendly reports.

Who Are The Prominent Organizations Shaping The Cardiovascular Genetic Testing Market?

Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.

Read the full cardiovascular genetic testing market report here:

https://www.thebusinessresearchcompany.com/report/cardiovascular-genetic-testing-market-report

Which Region Is Anticipated To See The Fastest Growth In The Cardiovascular Genetic Testing Market?

North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cardiovascular Genetic Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33054&type=smp

Browse Through More Reports Similar to the Global Cardiovascular Genetic Testing Market 2026, By The Business Research Company

Cardiovascular Clinical Trials Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-clinical-trials-global-market-report

Genetic Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Direct To Consumer Dtc Genetic Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/direct-to-consumer-dtc-genetic-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model